SCHEMBL5046414

SCHEMBL5046414

CCNc1cc2c(cn1)cc(-c1cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.65
LCK P06239 3/20 0.55
BTK Q06187 1/20 0.55
BRAF P15056 12/20 0.52
RAF1 P04049 12/20 0.52
ABL1 P00519 1/20 0.52
KDR P35968 3/20 0.52
MAPK14 Q16539 3/20 0.52
JAK3 P52333 2/20 0.52
TEK Q02763 1/20 0.52
DDR2 Q16832 1/20 0.51
MAPK13 O15264 1/20 0.51
LYN P07948 1/20 0.51
KIT P10721 1/20 0.51
PDGFRA P16234 1/20 0.51
MAPK12 P53778 1/20 0.51
EPHB4 P54760 1/20 0.51
EPHA4 P54764 1/20 0.51
MAPK11 Q15759 1/20 0.51
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14011563 0.92 SYK (0.63) SYKLCKBRAFRAF1ABL1
SCHEMBL14011539 0.91 SYK (0.68) SYKLCKBTKBRAFRAF1
SCHEMBL5046656 0.91 SYK (0.66) SYKLCKBTKBRAFRAF1
SCHEMBL14011533 0.90 SYK (0.61) SYKLCKBTKBRAFRAF1
SCHEMBL14011561 0.89 SYK (0.58) SYKLCKBRAFRAF1ABL1
SCHEMBL502335 0.89 SYK (0.65) SYKLCKBTKBRAFRAF1
SCHEMBL14011527 0.89 SYK (0.59) SYKLCKBTKBRAFRAF1
SCHEMBL14011549 0.89 SYK (0.61) SYKLCKBRAFRAF1ABL1
SCHEMBL10072197 0.89 SYK (0.67) SYKLCKBTKBRAFRAF1
SCHEMBL10043698 0.89 SYK (0.70) SYKLCKBTKBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1863774-B Compounds and compositions as protein kinase inhibitors IRM LLC 2010-12-15 CN disclosed
US-7449582-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-11-11 US disclosed
US-7449582-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-11-11 US disclosed
EP-1673343-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-10 EP disclosed
CN-1863774-A Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2006-11-15 CN disclosed
EP-1673343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-06-28 EP disclosed
US-20050187230-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-08-25 US disclosed
WO-2005034869-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187230-A1 Compounds and compositions as protein kinase inhibitors FYN, LCK, SRC SYK 30/4885LCK 2/4885BTK 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.